Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Down 85.7% in March

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 10,600 shares, a decline of 85.7% from the February 29th total of 74,000 shares. Based on an average daily trading volume, of 1,520,000 shares, the short-interest ratio is currently 0.0 days.

Provectus Biopharmaceuticals Stock Performance

Shares of OTCMKTS PVCT remained flat at $0.20 during midday trading on Wednesday. 464,715 shares of the stock were exchanged, compared to its average volume of 314,407. Provectus Biopharmaceuticals has a 52 week low of $0.06 and a 52 week high of $0.22. The stock’s fifty day moving average price is $0.15 and its 200 day moving average price is $0.12.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis; and PV-305 for the treatment of infectious keratitis.